Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer

Carcinogenesis

Volumn 30, Issue 6, 2009, Pages 1058-1063

  Glover, Cynthia E ^a,b   Gurley, Kay E ^a   Kim, Kyung Hoon ^a,c   Storer, Barry ^a   Fero, Mathew L ^a   Kemp, Christopher J ^a  

^a USA   (United States)

^b SNBL USA Ltd   (United States)

^c Immune Tolerance Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTRADIOL; PROGESTERONE; WNT1 PROTEIN; WNT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENDOCRINE DISEASE; ESTRADIOL BLOOD LEVEL; FEMALE; GENOTYPE; HYPOPHYSIS TUMOR; HYPOTHESIS; MALE; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; STOMACH TUMOR; TRANSGENIC MOUSE; ANIMAL; BLOOD; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; MOUSE MUTANT; NEOPLASM; PATHOLOGY;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ESTRADIOL; FEMALE; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASMS, HORMONE-DEPENDENT; OVARIECTOMY; PITUITARY NEOPLASMS; PROGESTERONE; STOMACH NEOPLASMS; WNT1 PROTEIN;

EID: 66849141218     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp089     Document Type: Article

References (46)

1. Sherr,C.J. et al. (1999) CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev., 13, 1501-1512.
2. Chu,I.M. et al. (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer, 8, 253-267.
3. Porter,P.L. et al. (2006) p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J. Natl Cancer Inst., 98, 1723-1731.
4. Pohl,G. et al. (2003) High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J. Clin. Oncol., 21, 3594-3600.
5. Pike,M.C. et al. (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev., 15 17-35.
6. Foster,J.S. et al. (2003) Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J. Biol. Chem., 278, 41355-41366.
7. Cariou,S. et al. (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl Acad. Sci. USA, 97, 9042-9046.
8. Pietenpol,J.A. et al. (1995) Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55, 1206-1210.
9. Kawamata,N. et al. (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res., 55, 2266-2269.
10. Spirin,K.S. et al. (1996) p27 mutation found in breast cancer. Cancer Res., 56, 2400-2404.
11. Fero,M.L. et al. (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature, 396, 177-180.
12. Nakayama,K. et al. (1996) Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85, 707-720.
13. Kiyokawa,H. et al. (1996) Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell, 85, 721-732.
14. Fero,M.L. et al. (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27-deficient mice. Cell, 85, 733-744.
15. Philipp-Staheli,J. et al. (2004) Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development. Oncogene, 23, 905-913.
16. Hwang,H.C. et al. (2002) Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc. Natl Acad. Sci. USA, 99, 11293-11298.
17. Martins,C.P. et al. (2002) Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J., 21, 3739-3748.
18. Geisen,C. et al. (2003) Loss of p27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis. Oncogene, 22, 1724-1729.
19. Di Cristofano,A. et al. (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet., 27 222-224.
20. Hikosaka,A. et al. (2008) Susceptibility of p27 kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine may not simply be due to enhanced proliferation. Int. J. Cancer, 122, 1222-1228.
21. Pellegata,N.S. et al. (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA, 103, 15558-15563.
22. Muraoka,R.S. et al. (2002) ErbB2/Neu-induced cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol., 22, 2204-2219.
23. Gao,H. et al. (2004) A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl Acad. Sci. USA, 101, 17204-17209.
24. Philipp-Staheli,J. et al. (2002) Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell, 1, 355-368.
25. Polakis,P. (2000) Wnt signaling and cancer. Genes Dev., 14, 1837-1851.
26. Tsukamoto,A.S. et al. (1988) Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell, 55, 619-625.
27. Rosner,A. et al. (2002) Pathway pathology: Histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am. J. Pathol., 161, 1087-1097.
28. Zhang,X. et al. (2005) Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene, 24, 4220-4231.
29. Bocchinfuso,W.P. et al. (1999) A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res., 59, 1869-1876.
30. Cardiff,R.D. et al. (2000) The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting. Oncogene, 19, 968-988.
31. Huang,S. et al. (2005) Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice. Genome Biol., 6, R84.
32. Li,Y. et al. (2000) Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene, 19, 1002-1009.
33. Jackson,R.J. et al. (2002) Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene, 21, 8486-8497.
34. Yu,Q. et al. (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature, 411, 1017-1021.
35. Vaillant,F. et al. (2008) The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res., 68, 7711-7717.
36. Liu,B.Y. et al. (2004) The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl Acad. Sci. USA, 101, 4158-4163.
37. Chien,W.M. et al. (2006) Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1. Proc. Natl Acad. Sci. USA, 103, 4122-4127.
38. Tong,W. et al. (1998) The absence of p27Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa→luteal transition. Cell Growth Differ., 9 787-794.
39. Ikeda,H. et al. (2001) Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice. Endocrine, 16, 55-65.
40. Kuzushita,N. et al. (2005) p27kip1 deficiency confers susceptibility to gastric carcinogenesis in Helicobacter pylori infected mice. Gastroenterology, 129, 1544-1556.
41. Yasui,W. et al. (1997) Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res., 88, 625-629.
42. Mori,M. et al. (1997) p27 expression and gastric carcinoma. Nat. Med., 3, 593.
43. Kim,D.H. et al. (2000) Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology, 36, 245-251.
44. Myung,N. et al. (2000) Loss of p16 and p27 is associated with progression of human gastric cancer. Cancer Lett., 153, 129-136.
45. Min,Y.H. et al. (2004) Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res., 64, 5225-5231.
46. Lindblad,M. et al. (2004) Estrogen and risk of gastric cancer: A protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol. Biomarkers Prev., 13, 2203-2207.